Table 8.
Ca2+ mobilization and chemotactic activity in human neutrophils treated with selected FPR1/FPRL1 agonists
| Compd. | Ca2+ flux | Chemotaxis |
|---|---|---|
| EC50 (µM) and Efficacy (%) a | ||
| 6a | 8.3 (100) | 15.9 |
| 6b | 1.0 (90) | 0.71 |
| 6c | 0.85 (110) | 0.70 |
| 6d | 2.4 (65) | 2.5 |
| 6e | 0.6 (115) | 0.60 |
| 11c | 6.1 (75) | 4.2 |
| 11d | 4.2 (130) | 1.9 |
| 11e | 6.0 (90) | 5.0 |
| 11i | 3.0 (125) | 1.5 |
| 11j | 3.9 (115) | 8.7 |
| 11k | 3.6 (80) | 3.9 |
| 11m | 4.9 (120) | 2.8 |
| 11p | 3.9 (75) | 2.1 |
| 11q | 2.4 (90) | 0.49 |
| 18 | 2.3 (115) | 0.87 |
| 23 | 3.9 (110) | 2.7 |
| 27 | 2.3 (100) | 0.8 |
| 28a | 2.1 (105) | 5.9 |
| 28b | 2.4 (110) | 1.9 |
| 33 | 3.0 (70) | 2.1 |
a
The data are presented as average mean of three independent experiments with cells from different donors, in which EC50 values were determined by nonlinear regression analysis of the dose-response curves (5–6 points) generated using GraphPad Prism 5 with 95% confidential interval (p<0.05).